Generic name:ranibizumab (intraocular route) [ ra-ni-BIZ-oo-mab ]
Drug class:Anti-angiogenic ophthalmic agents
Medically reviewed by Drugs.com. Last updated on Feb 1, 2022.
Warning: EndophthalmitisThe ranibizumab implant has been associated with a 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab. Many of these events were associated with conjunctival retractions or erosions. Appropriate conjunctiva management and early detection with surgical repair of conjunctival retractions or erosions may reduce the risk of endophthalmitis. In clinical trials, 2% of patients receiving a ranibizumab implant experienced at least one episode of endophthalmitis .
Commonly used brand name(s)
In the U.S.
- Byooviz
- Lucentis
- Susvimo
Available Dosage Forms:
- Solution
- Implant
Therapeutic Class: Ophthalmologic Agent
Pharmacologic Class: Monoclonal Antibody Fragment
Uses for Byooviz
Ranibizumab is used to treat neovascular (wet) age-related macular degeneration (AMD). Susvimo™ is used in patients who have responded to at least 2 injections of a vascular endothelial growth factor (VEGF) inhibitor. AMD is a disorder of the retina in the eye that causes blurring of vision or blindness. Ranibizumab works by changing the amount of blood that gets to the eye.
Ranibizumab is also used to treat myopic choroidal neovascularization (mCNV).
Ranibizumab is used to treat macular edema (swelling of the back of the eye) after retinal vein occlusion (a blood vessel in the eye is blocked). It is also used in diabetic patients who have diabetic macular edema (DME). Macular edema can cause loss of vision. This medicine is also used to treat diabetic retinopathy (eye problem caused by diabetes).
This medicine is to be given only by or under the direct supervision of your doctor.
Before using Byooviz
In deciding to use a medicine, the risks of taking ..
